small molecule

NEXTSTELLIS

DROSPIRENONE; ESTETROL

Loss of exclusivityOctober 2043latest FDA-listed patent expiry

CompanyMayne Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand name	NEXTSTELLIS
Active ingredient	DROSPIRENONE; ESTETROL
Strength	3MG;14.2MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	April 2021
Marketing status	RX

Listed patents

Patent	Expires	Type
12458649	October 2043	use U-3152
12233074	February 2043	product
11964055	June 2036	product
12427114	June 2036	product
11957694	June 2036	product
11793760	June 2036	product
7732430	January 2028	product

Regulatory exclusivity

Code	Expires
NCE	April 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Mayne Pharma